Nanjing Pharmaceutical Group Company Limited (SHA:600713)
China
· Delayed Price · Currency is CNY 5.44
+0.01 (0.18%)
Apr 29, 2026, 3:00 PM CST
SHA:600713 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 54,810 | 53,568 | 53,473 | 50,074 | 44,964 | Upgrade
|
| Other Revenue | 153.12 | 128.05 | 116.29 | 147.48 | 159.08 | Upgrade
|
| Revenue | 54,963 | 53,696 | 53,590 | 50,222 | 45,123 | Upgrade
|
| Revenue Growth (YoY) | 2.36% | 0.20% | 6.71% | 11.30% | 13.33% | Upgrade
|
| Cost of Revenue | 51,597 | 50,341 | 50,283 | 46,969 | 42,190 | Upgrade
|
| Gross Profit | 3,366 | 3,355 | 3,307 | 3,252 | 2,934 | Upgrade
|
| Selling, General & Admin | 1,713 | 1,666 | 1,691 | 1,645 | 1,509 | Upgrade
|
| Research & Development | 46.79 | 30.64 | 36.19 | 27.43 | 20.96 | Upgrade
|
| Other Operating Expenses | 116.34 | 94.31 | 96.35 | 116.55 | 91.37 | Upgrade
|
| Operating Expenses | 2,018 | 1,818 | 1,807 | 1,864 | 1,633 | Upgrade
|
| Operating Income | 1,349 | 1,537 | 1,500 | 1,389 | 1,301 | Upgrade
|
| Interest Expense | -309.01 | -325.82 | -522.23 | -332.9 | -439 | Upgrade
|
| Interest & Investment Income | 25.43 | 17.62 | 18.72 | 11.41 | 13.17 | Upgrade
|
| Other Non Operating Income (Expenses) | -217.58 | -218.47 | -19.42 | -136.95 | -17.44 | Upgrade
|
| EBT Excluding Unusual Items | 847.44 | 1,011 | 977.09 | 930.24 | 857.44 | Upgrade
|
| Impairment of Goodwill | -8.92 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.28 | - | - | -48.64 | -87.74 | Upgrade
|
| Gain (Loss) on Sale of Assets | 293.31 | 3.77 | 1.75 | 23.79 | 60.54 | Upgrade
|
| Other Unusual Items | 25.51 | -10.94 | -0.77 | 0.63 | 8.63 | Upgrade
|
| Pretax Income | 1,158 | 1,003 | 978.07 | 906.01 | 838.87 | Upgrade
|
| Income Tax Expense | 324.96 | 260.28 | 265.26 | 190.09 | 228.31 | Upgrade
|
| Earnings From Continuing Operations | 832.67 | 743.12 | 712.81 | 715.92 | 610.55 | Upgrade
|
| Minority Interest in Earnings | -207.83 | -172.49 | -134.98 | -120.25 | -105.37 | Upgrade
|
| Net Income | 624.83 | 570.63 | 577.83 | 595.67 | 505.18 | Upgrade
|
| Net Income to Common | 624.83 | 570.63 | 577.83 | 595.67 | 505.18 | Upgrade
|
| Net Income Growth | 9.50% | -1.25% | -3.00% | 17.91% | 34.21% | Upgrade
|
| Shares Outstanding (Basic) | 1,302 | 1,303 | 1,298 | 1,254 | 1,042 | Upgrade
|
| Shares Outstanding (Diluted) | 1,467 | 1,303 | 1,298 | 1,254 | 1,042 | Upgrade
|
| Shares Change (YoY) | 12.58% | 0.33% | 3.54% | 20.39% | -0.10% | Upgrade
|
| EPS (Basic) | 0.48 | 0.44 | 0.45 | 0.47 | 0.48 | Upgrade
|
| EPS (Diluted) | 0.43 | 0.44 | 0.45 | 0.47 | 0.48 | Upgrade
|
| EPS Growth | -2.74% | -1.57% | -6.32% | -2.06% | 34.35% | Upgrade
|
| Free Cash Flow | -159.57 | 1,591 | 1,748 | -837.59 | 388.79 | Upgrade
|
| Free Cash Flow Per Share | -0.11 | 1.22 | 1.35 | -0.67 | 0.37 | Upgrade
|
| Dividend Per Share | 0.170 | 0.170 | 0.160 | 0.140 | 0.120 | Upgrade
|
| Dividend Growth | - | 6.25% | 14.29% | 16.67% | 9.09% | Upgrade
|
| Gross Margin | 6.12% | 6.25% | 6.17% | 6.48% | 6.50% | Upgrade
|
| Operating Margin | 2.45% | 2.86% | 2.80% | 2.77% | 2.88% | Upgrade
|
| Profit Margin | 1.14% | 1.06% | 1.08% | 1.19% | 1.12% | Upgrade
|
| Free Cash Flow Margin | -0.29% | 2.96% | 3.26% | -1.67% | 0.86% | Upgrade
|
| EBITDA | 1,495 | 1,691 | 1,654 | 1,543 | 1,448 | Upgrade
|
| EBITDA Margin | 2.72% | 3.15% | 3.09% | 3.07% | 3.21% | Upgrade
|
| D&A For EBITDA | 146.15 | 154.02 | 153.76 | 153.84 | 147.27 | Upgrade
|
| EBIT | 1,349 | 1,537 | 1,500 | 1,389 | 1,301 | Upgrade
|
| EBIT Margin | 2.45% | 2.86% | 2.80% | 2.77% | 2.88% | Upgrade
|
| Effective Tax Rate | 28.07% | 25.94% | 27.12% | 20.98% | 27.22% | Upgrade
|
| Revenue as Reported | 54,963 | 53,696 | 53,590 | 50,222 | 45,123 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.